Caroline Subra, David Grand, Karine Laulagnier, Alexandre Stella, Gérard Lambeau, Michael Paillasse, Philippe De Medina, Bernard Monsarrat, Bertrand Perret, Sandrine Silvente-Poirot, Marc Poirot, Michel Record

Intercellular communication has been known for decades to involve either direct contact between cells or to operate by spreading molecules such as cytokines, growth factors, or lipid mediators. Through the last decade we have begun to appreciate the increasing importance of intercellular communication mediated by extracellular vesicles released by viable cells either from plasma membrane shedding microvesicles, also named microparticles), or from an intracellular compartment (exosomes). Exosomes and microvesicles circulate in all biological fluids and can trigger biological responses at distance. Their effects include a large variety of biological processes such as immune surveillance, modification of tumor microenvironment, or regulation of inflammation. They carry a large set of active molecules, including lipid mediators such as eicosanoids, proteins and nucleic acids, able to modify the phenotype of receiving cells. This review will highlight the role of the various lipidic pathways involved in the biogenesis and functions of microvesicles and exosomes.

Mammalian cells synthesize cholesterol through a series of 21 enzymatic steps, generating numerous metabolites that are involved in the control of physiological and developmental processes. Cholesterol itself is the precursor of steroid hormones and sterols, the latter of which can be further modified into molecules that induce specific biological responses. Epidemiological studies have investigated the role of cholesterol in breast cancer risk, with contradictory findings. Recent studies, however, linking cholesterol metabolism to breast cancer may provide some insights. Certain cholesterol metabolites can promote (1, 2) or suppress (3) breast cancer. This raises the important question of how to regulate or inhibit the cholesterol metabolic pathway, and at which steps, in a therapeutic approach to cancer.

We previously synthesized dendrogenin A and hypothesized that it could be a natural metabolite occurring in mammals. Here we explore this hypothesis and report the discovery of dendrogenin A in mammalian tissues and normal cells as an enzymatic product of the conjugation of 5,6α-epoxy-cholesterol and histamine. Dendrogenin A was not detected in cancer cell lines and was fivefold lower in human breast tumours compared with normal tissues, suggesting a deregulation of dendrogenin A metabolism during carcinogenesis. We established that dendrogenin A is a selective inhibitor of cholesterol epoxide hydrolase and it triggered tumour re-differentiation and growth control in mice and improved animal survival. The properties of dendrogenin A and its decreased level in tumours suggest a physiological function in maintaining cell integrity and differentiation. The discovery of dendrogenin A reveals a new metabolic pathway at the crossroads of cholesterol and histamine metabolism and the existence of steroidal alkaloids in mammals.